Profile data is unavailable for this security.
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
- Revenue in USD (TTM)20.22m
- Net income in USD-109.89m
- Incorporated2015
- Employees201.00
- Location4D Molecular Therapeutics Inc5858 Horton Street #455, EmeryvilleEMERYVILLE 94608United StatesUSA
- Phone+1 (510) 505-2680
- Fax+1 (302) 655-5049
- Websitehttps://4dmoleculartherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OmniAB Inc | 21.71m | -62.38m | 471.47m | 106.00 | -- | 1.60 | -- | 21.71 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -41.53m | 474.43m | 40.00 | -- | 3.66 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Regenxbio Inc | 89.04m | -241.08m | 480.39m | 344.00 | -- | 1.38 | -- | 5.40 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Tectonic Therapeutic Inc | 0.00 | -58.25m | 486.53m | 13.00 | -- | 2.92 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
ProKidney Corp | 0.00 | -38.68m | 491.00m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -299.80m | 497.05m | 130.00 | -- | 0.8727 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
Third Harmonic Bio Inc | 0.00 | -32.74m | 514.54m | 42.00 | -- | 1.99 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
4D Molecular Therapeutics Inc | 20.22m | -109.89m | 518.14m | 201.00 | -- | 0.8797 | -- | 25.63 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Alumis Inc | 0.00 | -189.03m | 529.89m | 128.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.57 | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Q32 Bio Inc | 0.00 | -65.02m | 539.68m | 41.00 | -- | 16.02 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Celcuity Inc | 0.00 | -82.59m | 556.93m | 55.00 | -- | 3.15 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Allogene Therapeutics Inc | 65.00k | -279.42m | 564.60m | 232.00 | -- | 1.10 | -- | 8,686.17 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Cartesian Therapeutics Inc | 54.10m | -229.65m | 585.87m | 38.00 | -- | -- | -- | 10.83 | -38.41 | -38.41 | 5.07 | -5.69 | 0.2221 | -- | 2.89 | 1,423,737.00 | -94.26 | -43.66 | -106.38 | -66.84 | -- | -- | -424.47 | -136.35 | -- | -0.3153 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 22 Jul 2024 | 7.26m | 14.04% |
RA Capital Management LPas of 31 Mar 2024 | 5.05m | 9.77% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 3.18m | 6.15% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.16m | 6.10% |
Deep Track Capital LPas of 31 Mar 2024 | 3.03m | 5.87% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 2.96m | 5.73% |
Viking Global Investors LPas of 31 Mar 2024 | 2.93m | 5.68% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.28m | 4.41% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.18m | 4.21% |
Polar Capital LLPas of 31 Mar 2024 | 1.80m | 3.48% |